SEC Form 4 · accession 0001061983-17-000017
CYTOKINETICS INC · CYTK
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Bradley Paul Morgan
Officer — SVP Drug Discovery & Early Dev
Period of report
Feb 28, 2017
Accepted (ET)
Mar 2, 2017 · 7:06 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001061983
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 28, 2017 | A | 15,000 | $0.001 | A | 31,180 | D | |
| Common Stock | Feb 28, 2017 | F | 5,986 | $10.60 | D | 25,194 | D | |
| Common StockF1 | Feb 28, 2017 | A | 20,000 | $0.001 | A | 45,194 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Incentive Stock Option (right to buy)F2 | $10.60 | Feb 28, 2017 | A | 6,463 | A | — | Feb 28, 2027 | Common Stock | 6,463 | 6,463 | D |
| Non-Qualified Stock Option (right to buy)F2 | $10.60 | Feb 28, 2017 | A | 13,537 | A | — | Feb 28, 2027 | Common Stock | 13,537 | 13,537 | D |
Explanation of responses
- F1The restricted stock units vest in three annual installments. Vested shares will be delivered to the reporting person as follows: 40% on 02/28/2018, 40% on 02/28/2019 and 20% on 02/28/2020.
- F2When the ISO and NQ dated 02/28/2017 are combined, the total grant shall vest and become exercisable in equal monthly installments such that the option shall be 100% vested on 02/28/2021.